The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase.

Nat Struct Biol. 1996 Apr;3(4):340-5. Unique Identifier : AIDSLINE MED/96185445
Grzesiek S; Bax A; Clore GM; Gronenborn AM; Hu JS; Kaufman J; Palmer I; Stahl SJ; Wingfield PT; Laboratory of Chemical Physics, National Institute of Diabetes; and Digestive and Kidney Diseases, National Institutes of Health,; Bethesda, Maryland 20892, USA.

Abstract: The solution structure of HIV-1 Nef has been solved by multidimensional heteronuclear NMR spectroscopy. The construct employed to circumvent problems associated with aggregation was a double-deletion mutant (delta2-39, delta159-173) in which conformationally disordered regions of the protein at the N terminus and in a long solvent-exposed flexible loop were removed, without affecting the properties or structural integrity of the remainder of the protein. Despite the absence of any sequence similarity, the overall fold of Nef is reminiscent of that of the family of winged helix-turn-helix DNA binding proteins. The binding surface of Nef for the SH3 domain of Hck tyrosine protein kinase has been mapped and reveals a non-contiguous (in terms of amino-acid sequence) interaction surface. This unique feature may suggest possible avenues for drug design aimed at inhibiting the interaction between Nef and SH3 domains.

Keywords: *src Homology Domains Amino Acid Sequence Binding Sites Gene Products, nef/*CHEMISTRY/METABOLISM Helix-Turn-Helix Motifs Human HIV-1/*CHEMISTRY Models, Molecular Molecular Sequence Data Nuclear Magnetic Resonance/METHODS Protein Conformation Protein Folding Protein Structure, Secondary Protein-Tyrosine Kinase/CHEMISTRY/*METABOLISM Proto-Oncogene Proteins/CHEMISTRY/*METABOLISM Sequence Deletion Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
960730
M9670513

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .